Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesClade, Country and Region-specific HIV-1 Vaccines: Are they necessary?HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogenTargeted killing of virally infected cells by radiolabeled antibodies to viral proteinsBiologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialNeutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloIdentifiable biomarker and treatment development using HIV-1 long term non-progressor sera.The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralizationBinding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virionsThe v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodiesNonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same siteNonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
P2860
Q24561905-49A76638-FB4E-45B5-86C7-73F81430F50AQ24803275-1C531561-D9E6-463E-90FF-F89B6058DCA6Q28390427-7A674DDD-6AA2-46FA-9EAA-70C0A80B6162Q28469068-49BC0DB9-3A64-4EF2-9593-16A550C76B4DQ33780524-BA5DA9A0-22BD-414E-BD2C-C38B15503A26Q33786222-D0EB5870-EE42-49C7-9090-D704ABA6B5ABQ33842152-05FA938A-2003-4B6B-91D7-DEBBF05DB84EQ34085098-74C4399E-0764-47B9-81C7-2DBB1DCEFB6CQ34145199-218F0DF1-B4D1-4259-9EF8-B3C40C955415Q34562259-40E989EB-B989-4011-8C3A-4B6A7215669AQ34637968-006001BE-75B0-4A96-B6B6-C9EE60188E87Q35024202-29C49A98-A6F5-4D19-B115-3B2F7D13EF3FQ35540731-F2EF10DF-F246-451C-A5DD-3BF8BDAFFA26Q35644971-F5C4A9C6-A30A-4BBC-B91E-E7E69E51F509Q35689608-6815422A-358E-416A-B145-7E838F9B4C88Q36954472-5180F4EC-D5C8-4E9B-B355-F7C5D48301B8Q37329415-DEFCB358-B621-4481-92B2-40C60DD94D38Q37436420-C1027E7D-8426-4E43-B6C9-8860CF1E56D9Q37744047-5F97A6CB-0383-4AF1-B3C5-69A7313438BBQ38739398-D55AA05C-4DFC-4E39-9FA9-F462841E53ADQ39699375-BADC9A1D-272A-42D1-A3F1-D37FEBC25420Q40274328-91AC175B-00F3-4FAF-A88A-040F529CD235Q42572387-53AE3B8E-1E98-44CA-AE1B-42697022D08DQ47547483-ED0592B2-019D-4683-81DD-EE6A39221E07
P2860
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Immunoreactivity of intact vir ...... -1 immunotypes than genotypes.
@ast
Immunoreactivity of intact vir ...... -1 immunotypes than genotypes.
@en
type
label
Immunoreactivity of intact vir ...... -1 immunotypes than genotypes.
@ast
Immunoreactivity of intact vir ...... -1 immunotypes than genotypes.
@en
prefLabel
Immunoreactivity of intact vir ...... -1 immunotypes than genotypes.
@ast
Immunoreactivity of intact vir ...... -1 immunotypes than genotypes.
@en
P2093
P2860
P1433
P1476
Immunoreactivity of intact vir ...... -1 immunotypes than genotypes.
@en
P2093
C Williams
P N Nyambi
S Zolla-Pazner
P2860
P304
10670-10680
P356
10.1128/JVI.74.22.10670-10680.2000
P577
2000-11-01T00:00:00Z